• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

环孢素A对分化为中性粒细胞的HL-60细胞中甲酸甲硫氨酰-亮氨酰-苯丙氨酸刺激反应的双相作用。

Biphasic effects of cyclosporin A on formyl-methionyl-leucyl-phenylalanine stimulated responses in HL-60 cells differentiated into neutrophils.

作者信息

Nguyen N S, Pulido S M, Rüegg U T

机构信息

Pharmacology Group, School of Pharmacy, University of Lausanne, Switzerland.

出版信息

Br J Pharmacol. 1998 Aug;124(8):1774-80. doi: 10.1038/sj.bjp.0702020.

DOI:10.1038/sj.bjp.0702020
PMID:9756396
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1565572/
Abstract

The immunosuppressive drug cyclosporin A (CsA) depresses neutrophil oxidative burst which may lead to an increased susceptibility to infection in transplant patients. Using specific CsA analogues we investigated the mechanism of inhibition of the oxidative burst and evaluated short and long-term effects of CsA on dimethylsulphoxide-differentiated HL-60 neutrophils. A biphasic pattern was observed: a 4 h pre-treatment with CsA (1 microM) diminished the fMLP induced [Ca2+]c rise, reactive oxygen species (ROS) production, and beta-glucuronidase release by about 40%, whereas a 20 h pre-treatment increased these responses by about 1.5 fold. [MeVal4]CsA, which binds with high affinity to cyclophilin but inhibits the interaction of the CsA-cyclophilin complex with calcineurin, blocked the stimulation observed with CsA after a 20 h incubation but did not alter the CsA effects after a 4 h pre-treatment. PSC 833 (1 microM), a potent multi drug resistance transporter (MDR) inhibitor, diminished ROS production to the same extent as a 4 h CsA incubation but was ineffective after a 20 h pre-treatment. An involvement of MDR as a basis for CsA or PSC 833 action was ruled out based on the results of the calcein retention assay. [3H]CsA uptake showed that CsA and [MeVal4]CsA, but not CsH or PSC 833 were strongly taken up and retained by the cells. In conclusion, the reduction of the responses after 4 h appear to be due to a primary reduction of calcium signalling, while the enhanced responses after 20 h may be due to calcineurin inhibition.

摘要

免疫抑制药物环孢素A(CsA)会抑制中性粒细胞的氧化爆发,这可能导致移植患者对感染的易感性增加。我们使用特定的CsA类似物研究了氧化爆发的抑制机制,并评估了CsA对经二甲亚砜分化的HL-60中性粒细胞的短期和长期影响。观察到一种双相模式:用CsA(1 microM)预处理4小时可使fMLP诱导的[Ca2+]c升高、活性氧(ROS)产生和β-葡萄糖醛酸酶释放减少约40%,而预处理20小时则使这些反应增加约1.5倍。[MeVal4]CsA与亲环蛋白具有高亲和力结合,但抑制CsA-亲环蛋白复合物与钙调神经磷酸酶的相互作用,在孵育20小时后阻断了CsA观察到的刺激,但在预处理4小时后未改变CsA的作用。PSC 833(1 microM)是一种有效的多药耐药转运蛋白(MDR)抑制剂,其降低ROS产生的程度与CsA孵育4小时相同,但在预处理20小时后无效。基于钙黄绿素保留试验的结果排除了MDR作为CsA或PSC 833作用基础的参与。[3H]CsA摄取表明,CsA和[MeVal4]CsA,但不是CsH或PSC 833被细胞强烈摄取并保留。总之,4小时后反应的降低似乎是由于钙信号的原发性降低,而20小时后反应增强可能是由于钙调神经磷酸酶的抑制。

相似文献

1
Biphasic effects of cyclosporin A on formyl-methionyl-leucyl-phenylalanine stimulated responses in HL-60 cells differentiated into neutrophils.环孢素A对分化为中性粒细胞的HL-60细胞中甲酸甲硫氨酰-亮氨酰-苯丙氨酸刺激反应的双相作用。
Br J Pharmacol. 1998 Aug;124(8):1774-80. doi: 10.1038/sj.bjp.0702020.
2
Differential inhibition of human neutrophil activation by cyclosporins A, D, and H. Cyclosporin H is a potent and effective inhibitor of formyl peptide-induced superoxide formation.环孢菌素A、D和H对人中性粒细胞活化的差异性抑制作用。环孢菌素H是甲酰肽诱导的超氧化物形成的一种强效且有效的抑制剂。
J Immunol. 1991 Sep 15;147(6):1940-6.
3
Cyclosporin H is a potent and selective formyl peptide receptor antagonist. Comparison with N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L- leucyl-L-phenylalanine and cyclosporins A, B, C, D, and E.环孢菌素H是一种强效且具有选择性的甲酰肽受体拮抗剂。与N-叔丁氧羰基-L-苯丙氨酰-L-亮氨酰-L-苯丙氨酰-L-亮氨酰-L-苯丙氨酸以及环孢菌素A、B、C、D和E的比较。
J Immunol. 1993 May 15;150(10):4591-9.
4
Cyclosporin H is a potent and selective competitive antagonist of human basophil activation by N-formyl-methionyl-leucyl-phenylalanine.环孢菌素H是一种强效且具有选择性的竞争性拮抗剂,可抑制N-甲酰甲硫氨酰-亮氨酰-苯丙氨酸对人嗜碱性粒细胞的激活作用。
J Allergy Clin Immunol. 1996 Jul;98(1):152-64. doi: 10.1016/s0091-6749(96)70237-3.
5
Inhibition of neutrophil responses by cyclosporin A. An insight into molecular mechanisms.环孢素A对中性粒细胞反应的抑制作用。对分子机制的深入了解。
Rheumatology (Oxford). 2001 Jul;40(7):794-800. doi: 10.1093/rheumatology/40.7.794.
6
The immunosuppressant cyclosporin A antagonizes human formyl peptide receptor through inhibition of cognate ligand binding.免疫抑制剂环孢素A通过抑制同源配体结合来拮抗人甲酰肽受体。
J Immunol. 2006 Nov 15;177(10):7050-8. doi: 10.4049/jimmunol.177.10.7050.
7
Cyclosporins: structure-activity relationships for the inhibition of the human FPR1 formylpeptide receptor.环孢菌素:抑制人FPR1甲酰肽受体的构效关系
J Med Chem. 2002 Oct 10;45(21):4613-28. doi: 10.1021/jm010987v.
8
Cyclosporin A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidyl-prolyl-cis-trans isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporin A-induced cytotoxicity.环孢素A通过诱导氧化应激和抑制亲环蛋白A的肽基脯氨酰顺反异构酶活性来阻断肌肉分化:亲环蛋白A可保护成肌细胞免受环孢素A诱导的细胞毒性。
FASEB J. 2002 Oct;16(12):1633-5. doi: 10.1096/fj.02-0060fje. Epub 2002 Aug 7.
9
N-formyl-Met-Leu-Phe-induced oxidative burst in DMSO-differentiated HL-60 cells requires active Hsp90, but not intact microtubules.N-甲酰甲硫氨酰-亮氨酰-苯丙氨酸诱导二甲基亚砜分化的HL-60细胞产生氧化爆发需要活性热休克蛋白90,但不需要完整的微管。
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2004 Dec;148(2):141-4.
10
The potent immunosuppressive cyclosporin FR901459 inhibits the human P-glycoprotein and formyl peptide receptor functions.强效免疫抑制剂环孢菌素FR901459可抑制人类P-糖蛋白和甲酰肽受体的功能。
J Antibiot (Tokyo). 2000 May;53(5):509-15. doi: 10.7164/antibiotics.53.509.

引用本文的文献

1
ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome.ABCB1基因分型可预测环孢素相关不良事件及肾移植预后。
J Am Soc Nephrol. 2009 Jun;20(6):1404-15. doi: 10.1681/ASN.2008080819. Epub 2009 May 21.
2
Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity.维甲酸刺激乳腺癌细胞中对氧化还原敏感的神经酰胺生成:在药物诱导的细胞毒性中的潜在作用。
Br J Cancer. 2004 Nov 15;91(10):1821-8. doi: 10.1038/sj.bjc.6602212.